$BPTH
BIO-PATH HOLDINGS, INC.

2024 Q4 Form 10-Q Financial Statement

#000155837024015717 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $1.317M
YoY Change -42.54%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.634M
YoY Change -19.6%
Operating Profit -$2.634M
YoY Change -19.6%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $519.0K
YoY Change 574.03%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.115M
YoY Change -33.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70
Diluted Earnings Per Share -$0.70
COMMON SHARES
Basic Shares Outstanding 4.307M 2.552M
Diluted Shares Outstanding 3.017M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $562.0K
Short-Term Investments
Other Short-Term Assets $1.806M
YoY Change 0.33%
Inventory
Prepaid Expenses $531.0K
Receivables
Other Receivables
Total Short-Term Assets $2.899M
YoY Change -39.63%
LONG-TERM ASSETS
Property, Plant & Equipment $42.00K
YoY Change -54.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $66.00K
YoY Change -69.86%
TOTAL ASSETS
Total Short-Term Assets $2.899M
Total Long-Term Assets $66.00K
Total Assets $2.965M
YoY Change -40.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.036M
YoY Change 245.33%
Accrued Expenses $2.313M
YoY Change 131.3%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.375M
YoY Change 148.71%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.375M
Total Long-Term Liabilities
Total Liabilities $3.677M
YoY Change 47.32%
SHAREHOLDERS EQUITY
Retained Earnings -$114.7M
YoY Change 10.09%
Common Stock $4.000K
YoY Change -63.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$700.0K
YoY Change
Total Liabilities & Shareholders Equity $2.965M
YoY Change -40.95%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.115M
YoY Change -33.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001133818
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
618000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3710000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36333
dei Entity Registrant Name
EntityRegistrantName
Bio-Path Holdings, Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
742-1357
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BPTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4306892
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
562000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1052000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
531000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
632000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1806000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1358000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2899000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3042000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1078000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1044000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
102000
CY2024Q3 us-gaap Assets
Assets
2965000
CY2023Q4 us-gaap Assets
Assets
3220000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1036000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
457000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2313000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1346000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3375000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1906000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
302000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10000
CY2024Q3 us-gaap Liabilities
Liabilities
3677000
CY2023Q4 us-gaap Liabilities
Liabilities
2779000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3710000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
618000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114032000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108047000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114748000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107607000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-712000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
441000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2965000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3220000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1317000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2292000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5478000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9332000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1317000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
984000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3889000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3478000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2634000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3276000
us-gaap Operating Expenses
OperatingExpenses
9367000
us-gaap Operating Expenses
OperatingExpenses
12810000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2634000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3276000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9367000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12810000
CY2024Q3 bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
-515000
CY2023Q3 bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
-72000
bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
-2216000
bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
-72000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
us-gaap Investment Income Interest
InvestmentIncomeInterest
32000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
519000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
77000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2226000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2115000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3199000
us-gaap Net Income Loss
NetIncomeLoss
-7141000
us-gaap Net Income Loss
NetIncomeLoss
-12706000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.36
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-29.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-29.34
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3017000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3017000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
503000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
503000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1763000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1763000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
433000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
433000
us-gaap Profit Loss
ProfitLoss
-7141000
us-gaap Profit Loss
ProfitLoss
-12706000
us-gaap Share Based Compensation
ShareBasedCompensation
439000
us-gaap Share Based Compensation
ShareBasedCompensation
554000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
78000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
71000
us-gaap Depreciation
Depreciation
34000
us-gaap Depreciation
Depreciation
66000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2216000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-72000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-101000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2955000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
448000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
174000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1546000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-335000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-87000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-80000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7694000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9721000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7204000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1689000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7204000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1689000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-490000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8032000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1052000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
562000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2352000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5043000
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
503000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
178000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3199000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2525000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1291000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-16000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
128000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2115000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-712000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14174000
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
503000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
554000
us-gaap Net Income Loss
NetIncomeLoss
-12706000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2525000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
441000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5549000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
439000
us-gaap Net Income Loss
NetIncomeLoss
-7141000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-712000
CY2024Q3 us-gaap Cash
Cash
600000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
302000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-700000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
400000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3710190
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-015717-index-headers.html Edgar Link pending
0001558370-24-015717-index.html Edgar Link pending
0001558370-24-015717.txt Edgar Link pending
0001558370-24-015717-xbrl.zip Edgar Link pending
bpth-20240930.xsd Edgar Link pending
bpth-20240930x10q.htm Edgar Link pending
bpth-20240930xex10d3.htm Edgar Link pending
bpth-20240930xex31.htm Edgar Link pending
bpth-20240930xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
bpth-20240930_def.xml Edgar Link unprocessable
bpth-20240930_lab.xml Edgar Link unprocessable
bpth-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bpth-20240930x10q_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bpth-20240930_cal.xml Edgar Link unprocessable